Cytotoxic CD8+ T cells are potent killers of diseased cells, but their functional capacity is
often compromised in cancer. The quality of antitumor T cell immunity is determined during T …

Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T
cell responses to model antigens, in various tumor settings. However, the impact of cross …

Dendritic cells are crucial for anti-tumor immune responses due to their ability to activate
cytotoxic effector CD8+ T cells. Canonically, in anti-tumor immunity, dendritic cells activate …

Immune checkpoint immunotherapy (ICI) can re-activate immune reactions against
neoantigens, leading to remarkable remission in cancer patients. Nevertheless, only a …

DCs have great promise for cancer immunotherapy and are essential for coordinating
immune responses. In the battle against cancer, using DCs' ability to stimulate the immune …

Immunopeptidomics is the area of knowledge focused on the study of peptides assembled in
the major histocompatibility complex (MHC), or human leukocyte antigen (HLA) in humans …

Background Intratumoral heterogeneity (ITH) and subclonal antigen expression blunt
antitumor immunity and are associated with poor responses to immune-checkpoint blockade …

Cross-presentation by type 1 cDCs (cDC1) is critical to induce and sustain antitumoral CD8
T cell responses to model antigens, in various tumor settings. However, the impact of cross …

The efficacy of immune checkpoint blockade (ICB) in NSCLC depends on the tumor
mutational burden (TMB). However, a fraction of patients with high TMB and predicted …

Colorectal cancer is the fourth most lethal cancer worldwide. Conventional cytotoxic
chemotherapy is the standard of care treatment for patients with advanced disease. The …